載入中
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
前收盤價
US$0.1299
−US$0.0021 · -1.59%
盤前
US$0.1298
−US$0.0001 · -0.08%
10月12日 上午7:41 ET
盤中時間採用ET。市場資料可能有所延遲。
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
日內區間
目前US$0.1299
52週區間
目前US$0.1299
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
41
合理估值
情緒
59
多空交錯
風險
63
高風險
動能
17
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
日內區間
目前US$0.1299
52週區間
目前US$0.1299
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 7500 USD | 68.6萬 USD | 28.4萬 USD | 11萬 USD |
| 毛利 | — | 7500 USD | 68.6萬 USD | 28.4萬 USD | 11萬 USD |
| 研究與開發 | 483.6萬 USD | 472.34萬 USD | 364.32萬 USD | 609.79萬 USD | 538.01萬 USD |
| 銷售、一般及管理費用 | 613.07萬 USD | 626.93萬 USD | 449.33萬 USD | 363.97萬 USD | 395.14萬 USD |
| 營業費用 | 1096.67萬 USD | 1099.26萬 USD | 813.65萬 USD | 973.76萬 USD | 933.15萬 USD |
| 利息收入 | 7.02萬 USD | 12.26萬 USD | 1577 USD | 4818 USD | 8759 USD |
| 利息支出 | 7587 USD | 1.22萬 USD | 16.77萬 USD | 25.19萬 USD | 6.7萬 USD |
| 折舊和攤銷 | 45.31萬 USD | 44.82萬 USD | 42.55萬 USD | 40.6萬 USD | 8.48萬 USD |
| 營業利益 | −1096.67萬 USD | −1098.51萬 USD | −745.05萬 USD | −945.36萬 USD | −922.15萬 USD |
| 淨利 | −1095.54萬 USD | −896.75萬 USD | −1128.38萬 USD | −1068.04萬 USD | −893.97萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年8月21日 | 6.66:1 | — | — |
股票分割 | 2024年7月1日 | 1:30 | — | — |
已生效 2025年8月21日
6.66:1
已生效 2024年7月1日
1:30
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
